- Home
- VANI vs MGNX Comparison
VANI vs MGNX Comparison
Compare VANI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- MGNX
- Stock Information
- Founded
- VANI 1998
- MGNX 2000
- Country
- VANI United States
- MGNX United States
- Employees
- VANI N/A
- MGNX N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- MGNX Health Care
- Exchange
- VANI Nasdaq
- MGNX Nasdaq
- Market Cap
- VANI 81.2M
- MGNX 94.9M
- IPO Year
- VANI 2014
- MGNX 2013
- Fundamental
- Price
- VANI $1.40
- MGNX $1.52
- Analyst Decision
- VANI Strong Buy
- MGNX Hold
- Analyst Count
- VANI 1
- MGNX 5
- Target Price
- VANI $4.00
- MGNX $3.20
- AVG Volume (30 Days)
- VANI 435.3K
- MGNX 922.2K
- Earning Date
- VANI 11-13-2025
- MGNX 11-12-2025
- Dividend Yield
- VANI N/A
- MGNX N/A
- EPS Growth
- VANI N/A
- MGNX N/A
- EPS
- VANI N/A
- MGNX N/A
- Revenue
- VANI N/A
- MGNX $127,626,000.00
- Revenue This Year
- VANI N/A
- MGNX N/A
- Revenue Next Year
- VANI N/A
- MGNX N/A
- P/E Ratio
- VANI N/A
- MGNX N/A
- Revenue Growth
- VANI N/A
- MGNX N/A
- 52 Week Low
- VANI $0.91
- MGNX $0.99
- 52 Week High
- VANI $1.92
- MGNX $3.77
- Technical
- Relative Strength Index (RSI)
- VANI 44.06
- MGNX 46.01
- Support Level
- VANI $1.36
- MGNX $1.30
- Resistance Level
- VANI $1.50
- MGNX $1.64
- Average True Range (ATR)
- VANI 0.11
- MGNX 0.11
- MACD
- VANI -0.02
- MGNX 0.00
- Stochastic Oscillator
- VANI 13.52
- MGNX 50.56
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.